A variety of other recurring mutations have been described in AML, most of which have a negative prognostic impact. Affected genes include ASXL1, NRAS, TP53, WT1, PHF6, RUNX1 and MLL-PTD.[51–55] Conclusions about the significance of these mutations cannot be made with great confidence due to their relative infrequency. In addition to mutational events, many other genes have been found to be either over- or under-expressed in AML and have associated prognostic value. Examples include MN1, BAALC, ERG, EVI1 and PRAME.[56–59]
Expert Rev Hematol. 2012;5(4):395-407. © 2012 Expert Reviews Ltd.